Importance: Persons infected with the human immunodeficiency virus (HIV) are at increased risk for major cardiovascular events compared to the general population. However, the prognosis of HIV-infected patients after these events is unknown. Objective: To determine whether in-hospital outcomes following acute myocardial infarction (AMI) and stroke differ between HIV-infected and uninfected persons, and whether these outcomes are associated with severity of HIV-induced immunosuppression. Design: Serial cross-sectional analysis using hospital discharge data from the Nationwide Inpatient Sample (NIS). Setting and Participants: Data from 18,370,325 hospitalizations from the NIS with a principal discharge diagnoses of AMI or stroke from January 1, 2002 to December 31, 2012. Main Outcome Measures: The primary study outcome was in-hospital mortality. The secondary outcome measures included length of stay and discharge to non-hospital inpatient facility. Results: HIV-infected persons were significantly younger than uninfected persons hospitalized for AMI (51.8 years vs 68.5 years; p < 0.001) and stroke (51.0 years vs 70.1 years; p < 0.001).
INTRODUCTION
Cardiovascular disease (CVD) has emerged as one of the leading causes of death in HIV-infected persons in the United States [2] [3] [4] . Data from several large cohort studies indicate that persons with HIV are at higher risk for acute myocardial infarction (AMI) than uninfected persons, even after adjusting for traditional CVD risk factors [2] [3] [4] . This increased risk of CVD may be linked to the severity of HIV-associated immunosuppression. For example, a recent study found no significant difference in the incidence rates of AMI among uninfected patients and patients with less advanced HIV infection 3 . By contrast, little is known about the relationship between severity of HIV infection and clinical outcomes in patients with AMI or stroke.
The current study examined the in-hospital outcomes of AMI and stroke in persons with HIV, stratified by a clinical history of the acquired immunodeficiency syndrome (AIDS), compared to uninfected persons. To accomplish this, we utilized the Nationwide Inpatient Sample (NIS), a registry of billing data for over 87 million all-payer hospitalizations in the United States. (Asymptomatic HIV), where the code could be listed on any position in the claim 6 . The "042" code is reserved for patients who have ever had a documented HIV related illness or met clinical criteria for AIDS, and is thus a surrogate indicator of current or prior severe HIV related immunosuppression. In the current study, persons with a history of AIDS were identified by an 
METHODS

Data Source and Case Ascertainment
Statistical Analysis
Unadjusted comparisons between patient characteristics and outcomes were calculated using weighted linear and logistic regression. Adjusted associations between HIV status and outcomes were evaluated using weighted logistic, negative binomial, and gamma log-link regressions as appropriate. The dataset was constructed using SAS System, version 9.4 (SAS Institute, Cary, NC), with analyses performed using Stata/MP, version 14.0 (Statacorp, College Station, Texas). Reported odds ratios were adjusted for age, sex and race/ethnicity. In order to more easily evaluate the findings, the adjusted results are also presented as incremental effects. A two-sided alpha level of 0.05 was considered statistically significant. Authorization for this study and a waiver of informed consent were obtained from the University of North Carolina Institutional Review Board. Between 2002 and 2012, there were 8,233,608 AMI hospitalizations and 10,136,717 stroke hospitalizations in the United States, based on weighted estimates of inpatient admissions included in the NIS database ( Table 1) . Of these hospitalizations, 48,993 had a billing diagnosis code for HIV (21,117 AMI hospitalizations and 27,816 stroke hospitalizations).
RESULTS
AMI Hospitalization Outcomes by HIV Status
HIV-infected persons hospitalized for AMI were significantly younger than uninfected persons (51.8 years versus 68.6 years; p = < 0.001). There was also a higher proportion of Blacks (39.1% v. 9.5%, p < 0.001) and lower proportion of females (19.2% v. 41.3%, p < 0.001) in the HIV-infected group. Although hospitalizations for AMI decreased by 12% during the study period among uninfected persons, they increased by 21% among persons with a history of AIDS and by 83% among infected persons without a history of AIDS (p = <0.001 for trend; Figure 1 ). Table 2 ). By contrast, the duration of hospitalizations for AMI for persons without a history of AIDS was significantly shorter (adjusted difference -0.9 days, 95% CI -0.7, -1.0), p < 0.0001) than that of uninfected persons ( hospitalizations among persons with a history of AIDS were 28% longer than those of uninfected persons (adjusted difference 1.6 days, 95% CI 0.7, 2.5 days, p <0.001; Table 3 ). However, stroke hospitalizations among persons with asymptomatic HIV were actually slightly shorter than those of uninfected persons (adjusted difference -0.5 days 95% CI -0.1, -0.8 days).
Stroke hospitalizations in infected persons with a history of with AIDS were also more likely to result in discharge to a non-hospital inpatient facility than those of uninfected persons (OR 1.43, 95% CI 1.11, 1.85; Figure 3 ). Infected persons without a history of AIDS were only slightly more likely to be discharged to non-hospital inpatient care than uninfected persons (OR 1.11, 95% CI 1.00, 1.23). After adjusting for risk factors, persons with a history of AIDS had a significantly higher risk for in-hospital mortality after a stroke than uninfected persons (OR 2.52, Our study increases the understanding of non-AIDS clinical consequences of chronic HIV infection. We found that HIV-infected patients who developed AMI or stroke were more than twice as likely to die as uninfected patients with the same CVD event, and that most of this mortality risk was borne by patients with a history of AIDS. Clarifying the disproportionate distribution of CVD-associated risk among HIV-infected patients is important because of the growing overlap between the two epidemics. Given that over half of HIV-infected persons living in the United States will be aged 50 years or older by 2017 9 , the number of HIV-infected patients with CVD will continue to climb. Thus, there is an urgent need to improve our understanding of CVD in this population.
Exposure to HIV-induced immunosuppression has been linked to an increased risk of many non-AIDS conditions [11] [12] [13] [14] . CD4 nadirs of < 350 cells/mm 3 are associated with surrogates of atherosclerosis 15, 16 , including increased carotid intimal-medial thickness (cIMT) and decreased arterial compliance (indicated by flow-mediated dilatation). Low CD4 nadirs have also been associated with increased levels of the inflammatory marker IL-6 17 , sustained hypertension and left ventricular hypertrophy. 18, 19 These findings of adverse vascular physiology associated with severe HIV-induced immunosuppression appear to corroborate published clinical experience.
For example, two large studies of the Northern California Kaiser Permanente cohort showed that HIV-infected persons with a CD4 count of ≤ 200 cells/mm 3 had a 74% higher incidence of AMI and a 60% higher incidence of stroke than uninfected persons. Interestingly, there was no significant difference between the incidence rate of AMI and stroke in HIV-infected cohort members with CD4 nadir ≥ 500 cells/mm 3 and uninfected persons 3, 20 . The current study counts, we believe that the billing code for AIDS is a surrogate for low CD4 nadir, and we can postulate that persons with a billing code for AIDS had lower CD4 nadir than persons with a billing code for AIDS overall. Finally, we did not have access to indicators of patient acuity on presentation and thus a potential confounder related to inpatient prognosis was not addressed by our analysis.
In summary, our study demonstrates that persons with a history of AIDS hospitalized for AMI or stroke have longer inpatient length of stay, are more likely to be discharged to nonhospital inpatient care and are significantly more likely to die while hospitalized than uninfected persons. By contrast, there is no significant difference in AMI and stroke hospital outcomes between persons with asymptomatic HIV and uninfected persons. Future studies are needed to confirm these findings and to better understand their biological basis. In the meantime, our data 228 230   231  232  233  234  235  236  237  238  239  240  241  242  243  244  245  246  247  248  249  250  251  252  253  254  255  256  257  258  259  260  261  262  263  264  265  266  267  268  269  270  271  272  273  274  275  276  277  278  279 19. 
